Results 181 to 190 of about 9,288 (216)

Entry of cystic fibrosis transmembrane conductance potentiator ivacaftor into the developing brain and lung

Journal of Cystic Fibrosis, 2021
Elena K Schneider-Futschik, Yifan Huang, Mark Habgood   +2 more
exaly  

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele

American Journal of Respiratory and Critical Care Medicine, 2021
Samuel Moskowitz, Mcnally P, Bonnie Ramsey   +2 more
exaly  

Ivacaftor/lumacaftor

Reactions Weekly, 2022
openaire   +1 more source

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events

Journal of Cystic Fibrosis, 2021
Carsten Schwarz, Ralph Epaud, Rainald Fischer   +2 more
exaly  

Ivacaftor/lumacaftor

Reactions Weekly, 2023
openaire   +1 more source

Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis

American Journal of Respiratory and Critical Care Medicine, 2020
Dominique Hubert, Prévotat Anne, Laurence Weiss   +2 more
exaly  

Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis

Journal of Cystic Fibrosis, 2022
Max Petersen
exaly  

Ivacaftor

Reactions Weekly, 2019
openaire   +1 more source

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation

Journal of Cystic Fibrosis, 2014
Albert Faro, Mark Higgins, Kris De Boeck   +2 more
exaly  

Accumulation and persistence of ivacaftor in airway epithelia with prolonged treatment

Journal of Cystic Fibrosis, 2020
Charles Esther, Deborah Cholon, Martina Gentzsch   +2 more
exaly